Coronavirus breakthrough: China becomes first to use experimental vaccine

We will use your email address only for sending you newsletters. Please see our Privacy Notice for details of your data protection rights.

The vaccine was developed by the People’s Liberation Army together with a Chinese pharmaceutical company. The titled Ad5-nCoV vaccine was reportedly jointly created by a team at the Academic Military Medical Sciences.

The development was led by Major General Chen Wei and Tianjin-based company CanSino Biologics.

It will be the first time a Covid-19 vaccine has be authorised for use for the military of a nation.

On Monday, CanSino said that the vaccine had been through two phases of clinical trials.

The phases indicated that it was safe and there was “relatively high” immune response to the antigen.

However, the vaccine is yet to start phase three trials.

These would confirm whether it can actually protect people from coronavirus infection.

The Chinese military has reportedly approved its use for a year but has not yet authorised it for civilian purposes.

The new candidate is based on an Ebola vaccine that was developed by Major General Chen Wei.

At the time, this specific Ebola vaccine did not go into mass production.

Scientists across the world are racing to find vaccines and treatments amind the coronavirus pandemic that has already killed over 500,000 people.

In the US, new cases are continuing to surge.

On Monday, America confirmed over 40,000 new cases for the third consecutive day.

Prince William marks new royal first in visit to see vaccine trial [UPDATE]
Former Health Minister calls for COVID-19 vaccine to provide long-term [INSIGHT]
Oxford COVID vaccine on track for autumn release after ‘good results’ [ANALYSIS]

The World Health Organisation have said that clinical trials are under way for 17 vaccines.

Seven of these have been developed in China.

A vaccine developed by Oxford University and AstraZeneca is reportedly currently in phase three studies.

Phase one and two trails normally test whether a candidate is safe and if it can form an immune response from a person.

Vaccines have to complete all three stages of trails in order to be licensed.

CaSino in China announced that it had completed phase two of trails on 11 June.

However, the company has yet to release data from the study.

Source: Read Full Article